Skip to main content

Want a detailed portfolio tracker?

Performance analysis of Intensity Therapeutics (INTS)

Annual Return

Since Jun 30, 2023, INTS has had an average annual return of -70.29%, underperforming the benchmark SPY, which returned +21.64% annual.

2026202520242023
-58.28%-76.70%-79.46%+43.79%

Monthly Return

YearJanFebMarAprMayJunJulAugSepOctNovDecAnnually Total
2026-10.90%-16.15%-23.15%-11.39%-15.71%-2.71%-58.28%
2025+25.57%+5.88%-15.82%-70.14%-19.25%-35.38%-9.71%+1.72%-13.95%+200.98%-45.31%+2.69%-76.70%
2024-42.59%-24.80%+40.54%-25.00%+27.43%-1.42%-1.22%-10.12%-12.19%-14.92%-9.98%-39.85%-79.46%
2023+0%-4.03%+0.88%-31.20%-23.68%-19.12%+249.68%+43.79%

Drawdown analysis of Intensity Therapeutics (INTS)

The maximum drawdown for the INTS was -98.27%, occurring on Jun 2, 2026. This drawdown has not yet recovered.

The current INTS drawdown is -98.27%.

Since Jun 30, 2023 INTS has experienced the following drawdowns:

  • 50% or more: 2 times
  • 40% or more: 2 times
  • 30% or more: 2 times
  • 20% or more: 2 times
  • 10% or more: 2 times
DepthStartTo BottomBottomTo RecoverEndTotal
-98.27%Dec 13, 2023617Jun 2, 2026OngoingOngoingOngoing
-67.50%Jul 18, 202386Nov 16, 202315Dec 8, 2023101
-8.87%Jul 3, 20237Jul 13, 20233Jul 18, 202310